Efficacy and Safety of JS016 in Patients With SARS-CoV-2 Infection (COVID-19)
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The human monoclonal antibody CB6 showed potent neutralization activity in vitro against
SARS-CoV-2. CB6-LALA (also called JS016) has been developed for clinical use. Phase I trials
among healthy volunteers has demonstrated a tolerable and safe drug profile of JS016. We aim
to evaluate the efficacy and safety of JS016 in patients hospitalized with COVID-19.